These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32694196)

  • 21. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia.
    Lister J; Andreazza AC; Navaid B; Wilson VS; Teo C; Nesarajah Y; Wilson AA; Nobrega JN; Fletcher PJ; Remington G
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():23-29. PubMed ID: 27565433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.
    Nel A; Harvey BH
    Behav Pharmacol; 2003 May; 14(3):251-5. PubMed ID: 12799528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
    Turrone P; Remington G; Kapur S; Nobrega JN
    Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.
    McCullumsmith RE; Stincic TL; Agrawal SM; Meador-Woodruff JH
    Eur J Pharmacol; 2003 Sep; 477(2):101-12. PubMed ID: 14519413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
    Hashimoto T; Ross DE; Gao XM; Medoff DR; Tamminga CA
    Psychopharmacology (Berl); 1998 May; 137(2):107-12. PubMed ID: 9629996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
    Bishnoi M; Chopra K; Kulkarni SK
    Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol versus risperidone on rat "early onset" vacuous chewing.
    Marchese G; Bartholini F; Casu MA; Ruiu S; Casti P; Congeddu E; Tambaro S; Pani L
    Behav Brain Res; 2004 Feb; 149(1):9-16. PubMed ID: 14739005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
    An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Kosten TR; Zhou DF; Yang FD; Zhang XY
    Behav Pharmacol; 2013 Oct; 24(7):610-6. PubMed ID: 23994817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
    Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
    Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.
    Sadan O; Bahat-Stromza M; Gilgun-Sherki Y; Atlas D; Melamed E; Offen D
    Clin Neuropharmacol; 2005; 28(6):285-8. PubMed ID: 16340385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gabapentin reduces haloperidol-induced vacuous chewing movements in mice.
    Ceretta APC; de Freitas CM; Schaffer LF; Reinheimer JB; Dotto MM; de Moraes Reis E; Scussel R; Machado-de-Ávila RA; Fachinetto R
    Pharmacol Biochem Behav; 2018 Mar; 166():21-26. PubMed ID: 29374574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
    Burger ME; Fachineto R; Alves A; Callegari L; Rocha JB
    Brain Res; 2005 Jan; 1031(2):202-10. PubMed ID: 15649445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.
    De Souza IE; Dawson NM; Clifford JJ; Waddington JL; Meredith GE
    Psychopharmacology (Berl); 2003 Aug; 169(1):28-34. PubMed ID: 12830366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
    Hyde TM; Egan MF; Wing LL; Wyatt RJ; Weinberger DR; Kleinman JE
    Psychopharmacology (Berl); 1995 Mar; 118(2):142-9. PubMed ID: 7617800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice.
    Crowley JJ; Ashraf-Khorassani M; Castagnoli N; Sullivan PF
    Neurotoxicology; 2013 Dec; 39():153-7. PubMed ID: 24107597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.